Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter …

E Abraham, R Wunderink, H Silverman, TM Perl… - Jama, 1995 - jamanetwork.com
Objective.—To evaluate the efficacy and safety of anti—tumor necrosis factor α monoclonal
antibody (TNF-α MAb) in the treatment of patients with sepsis syndrome. Design.—
Randomized, prospective, multicenter, double-blind, placebo-controlled clinical trial. Setting.—
A total of 31 hospitals in the United States and Canada. Patients.—There were 994 patients
with sepsis syndrome enrolled in this clinical trial, and 971 patients were infused with the
study drug. Intervention.—Patients were prospectively stratified into shock or nonshock …